Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.
HAEMATOLOGICA(2018)
摘要
Patients with Philadelphia chromosome-like B-cell lymphoblastic leukemia (Ph-like or BCR-ABL1 -like BALL) experience high relapse rates and are difficult to cure with conventional chemotherapy.[1][1],[2][2] The Ph-like ALL subtype comprises 15-25% of B-ALL in older children and adolescents/young
更多查看译文
关键词
Kinase Inhibitors,Minimal Residual Disease,Pediatric Acute Lymphoblastic Leukemia
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络